

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement*



## **CHINA HEALTH GROUP INC.**

### **中國醫療集團有限公司**

**(Carrying on business in Hong Kong as “萬全醫療集團”)  
(Incorporated in the Cayman Islands with limited liability)  
(Stock Code: 08225)**

#### **(1) Additional English translation of the clarification**

#### **(2) Unusual Price/Turnover Movements**

#### **(3) RESUMPTION OF TRADING**

#### **Additional English translation of the clarification**

Reference is made to notice of China Health Group Inc. (the “Company” ) dated 24 January 2020 in relation to RWS Special Group Spring Festival in Action (hereinafter referred to as “the notice” ) , this notice is additional English translation of the notice. Unless otherwise stated, capitalised terms used in this notice shall

have the same meaning as those defined in the notice.

Clinical big data screening center for anti coronavirus drugs, China Health Group announced the outbreak of pneumonia caused by new coronavirus infection. The group set up a special action group for digital clinical research, led by Dr. Song Xuemei, who is engaged in clinical research in the fight against the SARS epidemic. With experts from Peking University Union Medical College and Wuhan Tongji University, the group selected the drugs to overcome the epidemic and carried out the corresponding RWS research.

Wanquan Wante Xiamen Pharmaceutical Co. , an affiliate of China Health Group, produces oral suspension of Lopinavir and Ritonavir, STATE MEDICAL PERMITMENT No H20040411: STATE MEDICAL PERMITMENT No H20051019 to become the health commission issued a new national version of the diagnosis and treatment of pneumonia revised version of the two recommended drugs: Antiviral trial- $\alpha$  interferon, Lopinavir Ritonavir.

Wang Guangfa, director of respiratory and Critical Care Medicine at Peking University First Hospital, recovered from coronavirus infection using the drug. In a clinical trial, 41 Hong Kong SARS patients were treated for three weeks the protocol is " Lopinavir ,

Ritonavir, " plus Ribavirin, Welling. Ribavirin was not a cure for SARS, but as a antiviral drug, it was used clinically to treat SARS patients, the very drugs they were supposed to be taking. After treatment, the mortality rate was only 2.4 %, the study found. As a reference, the researchers'Hong Kong hospital had routinely treated 111 SARS patients before April 16,2003, with a mortality rate of 28.8% .

The RWS Clinical Research Center of the Chinese Health Group is conducting research during the Spring Festival. The center has played an important role in several outbreaks in China, such as the RWS Group providing extremely important clinical big data in the SARS sniping

During the outbreak,Pseudo-science abounds, many so-called "donkey skin, " "Banlangen, " "pestilence, " "VC, " "Shuanghuanglian, " "thymic peptides, " without the support of clinical big data. RWS special group, RWS and RCT clinical big data screening recommended the epidemic one batch of adjuvant drugs.

Kalinin has been credited with fighting the flu that causes cough, Phlegm and other respiratory diseases, including COPD. Zhong won an award for his article in the Leading Lancet.

RWS clinical research: more than ten traditional Chinese medicines such as carcinogens containing aristolochic acid are forbidden for

cough drugs; dozens of cough chemicals such as codeine are used cautiously for children; and cold cough drugs such as amantadine ibuprofen and Pudilan are used cautiously.

Yueting smoking cessation clinical research group are ready to help smokers recover from new viral pneumonia.

Refute the treatment of new virus pneumonia by smoking, and prove that smoking is a disease by clinical data. It is necessary to treat the harm of dry and quit. Yueting quit smoking, lung disease, cardiovascular and cancer prevention and treatment first. The infection of smoking population is higher. 1. Reduce the respiratory. 2. Repeated hand contact with a cigarette holder. 3. No masks. 4. Smoking Causes Lung Cancer, blocked lungs, heart failure

RWS xienjieyou medical group, through clinical research, used lefuting, Quyou, and mcwei products to relieve depression symptoms of patients and their families, and improve the patient's autoimmune system to fight against new pneumonia.

China Health Group is a research and development-based digital medical group, Venturepharma Group is a research and development-driven digital ecological pharmaceutical group.

## **Unusual Price/Turnover Movements**

The board (the “Board”) of directors (the “Directors”) of the Company has noted the unusual movement in the trading price and trading volume of the shares of the Company today. Having made such enquiry with respect to the Company as is reasonable in the circumstances, the Board confirms that it is not aware of any reasons for the aforesaid price and trading volume movements or of any information which must be announced to avoid a false market in the Company’s securities or of any inside information that needs to be disclosed under Part VIXA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

## **RESUMPTION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange was halted with effect from 1:28 p.m. on 29 January 2020 pending the release of this announcement. The Company has applied to the Stock Exchange for resumption of trading in the shares of the Company with effect from 9:00 a.m. on 30 January 2020.

**By order of the Board**

**China Health Group Inc.**

**GUO Xia**

**Chairman**

**Hong Kong, 29 January 2020**

*As at the date hereof, the Board comprises two executive Directors, being Mr. GUO Xia and Dr. SONG Xuemei; one non-executive Director, being Mr. SU Yi; and three independent non-executive Directors, being Mr. QIU Rui, Dr. NI Binhui and Mr. ZHEN Ling. This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading. This announcement will remain on the "Latest Listed Company Information" page of the GEM website at <http://www.hkgem.com> for 7 days from the date of its posting. This announcement will also be posted on the Company's website at <http://www.chgi.net>.*